Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965190 | 0.92 | HTR2A (0.43) | HTR2ATP53MAPTGAATHRB | |
| SCHEMBL4963522 | 0.87 | PPARG (0.43) | TP53MAPTUSP2HSD17B10TRPM8 | |
| SCHEMBL4965244 | 0.85 | MAPT (0.46) | TP53MAPTGAATRPM8HTT | |
| SCHEMBL4964263 | 0.84 | HSP90AA1 (0.44) | MAPTHTT | |
| SCHEMBL4962717 | 0.83 | TRPM8 (0.53) | TP53MAPTGAATHRBHSD17B10 | |
| SCHEMBL4764980 | 0.82 | FFAR4 (0.43) | HTR2AMAPTFFAR4KCNK3KCNK5 | |
| SCHEMBL4963743 | 0.79 | TRPM8 (0.59) | HSD17B10TRPM8 | |
| SCHEMBL4963240 | 0.79 | PPARD (0.44) | TP53MAPTUSP2HSD17B10 | |
| SCHEMBL4961998 | 0.78 | KDM4E (0.43) | HTR2AMAPTHTT | |
| SCHEMBL4631046 | 0.77 | PPARG (0.42) | HTR2AMAPTFFAR4KCNK3KCNK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351858-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| EP-1517679-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB, R&D HEADQUARTERS, GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1517679-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000294-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | INSR, GPR119, IRS1 | HTR2A 4216/4885TP53 4383/4885MAPT 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.